谷氨决定了慢性髓性白血病对CMPK和TMPK抑制剂的脆弱性
Chang-Yu Huang1, Yin-Hsuan Chung1, Sheng-Yang Wu1
1Institute of Molecular Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Communications biology
|July 10, 2024
概括
一种名为JMF4073的新化合物,向胺基酸和胺基酸激酶治疗慢性髓性白血病 (CML). 它通过克服涉及谷氨 (GSH) 的抵抗机制,对抗TCI耐药CML具有前途.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 慢性髓性白血病 (CML) 是由Bcr-Abl融合蛋白驱动的.
- T315I突变赋予了对氨酸激酶抑制剂 (TKI) 的耐药性,这是CML治疗的一个主要挑战.
研究的目的:
- 调查JMF4073,一种新型的基酸盐 (TMP) 和基酸盐 (CMP) 激酶抑制剂,作为TKI抗性CML的潜在治疗方法.
- 阐明T315I突变的CML细胞中对JMF4073的耐药性机制,并确定克服它的策略.
主要方法:
- 使用Bcr-Abl转化细胞系 (WT和T315I突变) 的体外和体内研究.
- 分析ATF4和谷氨 (GSH) 在JMF4073耐药性中的作用.
- 在人类CML爆发危机细胞系中对JMF4073和GSH降低剂的联合治疗的评估.
主要成果:
- 虽然JMF4073有效地消除了WT-Bcr-Abl-32D的CML细胞,但对T315I-Bcr-Abl-32D细胞的疗效却有所降低.
- 通过ATF4调节的GSH被确定为T315I突变细胞中的抵抗机制.
- 通过诱导复制应激,减少GSH生物合成使T315I-Bcr-Abl-32D细胞对JMF4073敏感.
- 人类CML爆发危机细胞系显示ATF4/GSH水平与JMF4073敏感度之间存在逆相关性.
- 结合治疗JMF4073与一个GSH降低剂导致合成致死性在CML爆发危机线.
结论:
- JMF4073显示出作为CML治疗剂的潜力,特别是针对TKI耐药的形式.
- 针对GSH生物合成与JMF4073一起,为TKI抗性CML提供了一种新的合成致命策略.
- 这种方法为患有晚期或耐药性CML的患者提供了一个有前途的替代治疗选择.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


